ARTEMIS Synovial Markers in Arthritis Childhood
This trial is active, not recruiting.
|Conditions||septic arthritis, juvenile idiopathic arthritis|
|Treatment||articular punction, salivary samples, blood sample|
|Sponsor||University Hospital, Montpellier|
|Start date||April 2015|
|End date||April 2017|
|Trial size||30 participants|
|Trial identifier||NCT02505828, 2014-A01561-46, 93612|
The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.
|Intervention model||single group assignment|
|Masking||single blind (subject)|
Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis.
time frame: 1 day
Male or female participants from 6 months up to 18 years old.
Inclusion Criteria: - Septic arthritis with bacteriological identification - Juvenile idiopathic arthritis beyond the ILAR definition - Having acute arthritis requiring an articular draining - Child benefiting from a national insurance scheme - Collection of the consent of the parents or the legal representative Exclusion Criteria: - Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)> 1,5 - Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining. - Treatment by antibiotic begun more than 24 hours before the draining.
|Official title||ARTEMIS Synovial Markers in Arthritis Childhood|
|Principal investigator||Eric EJ JEZIORSKI, MD, PhD|
Call for more information